Other names
Types
Causes
Symptoms
Diagnostic tests
Drug treatments
Immunity-booster / regenerative / stem-cell” drugs
Surgeries (procedures and why they’re done)
Preventions
When to see a doctor urgently
Foods to prefer and to limit/avoid
Frequently asked questions

Birdshot choroidal lesions are pale, oval or round spots deep in the back of the eye. They sit in the choroid, which is the layer that feeds the retina. These spots look “cream-colored,” often around the optic nerve and toward the mid-periphery, and they tend to point away from the optic disc like “birdshot pellets.” They are part of a chronic, autoimmune eye inflammation called birdshot chorioretinopathy (BCR). The disease usually affects both eyes, causes floaters, blurred or dim vision, poor night vision, and trouble with color and contrast. Many people with this disease carry a genetic marker called HLA-A29. The condition is non-infectious (not caused by bacteria or virus) and can flare and quiet down over time. The main risk to sight is swelling in the center of the retina (cystoid macular edema), inflammation of the retinal vessels (vasculitis), and slow loss of retinal function if not controlled.

Birdshot choroidal lesions are cream-colored, oval or elongated patches in the back of the eye (the choroid and retina). They appear in both eyes, usually spread around the optic nerve, and point outward like a “birdshot” pattern. These lesions are the hallmark of birdshot chorioretinopathy (BCR)—a rare, chronic, autoimmune posterior uveitis strongly linked to the HLA-A29 tissue type. People often develop night-vision trouble, floaters, color desaturation, glare, and gradually declining vision if inflammation is not controlled. Diagnosis combines the look of lesions, imaging tests (like OCT, fluorescein angiography, indocyanine green angiography), electroretinography, and HLA-A29 testing to support the impression. Early recognition matters because timely anti-inflammatory treatment can preserve vision. BioMed Central+3AAO+3NCBI+3

Other names

You may see several names for the same condition or for the lesions it causes. They refer to the same general disease picture.

Birdshot chorioretinopathy (BCR): the common clinical name.
Birdshot retinochoroidopathy: emphasizes both retina and choroid.
Birdshot uveitis: highlights that this is a type of uveitis (eye inflammation).
Vitiliginous chorioretinitis: older name describing the pale, “depigmented” spots.
HLA-A29–associated uveitis: stresses the strong genetic link.
Idiopathic bilateral stromal choroiditis: descriptive research term.
Birdshot choroiditis: short clinic term, often used interchangeably.

All these labels point to the same core idea: a bilateral, HLA-A29–linked, non-infectious choroid-retina inflammation with classic cream spots.

Types

Doctors do not use one universal staging scale, but they describe “types” in practical ways that help guide care:

By activity
- Active lesions: new or “fresh” cream spots with haze from inflammation; vision symptoms are more noticeable.
- Inactive (healed) lesions: flatter, well-defined, pale spots with less surrounding haze; symptoms may be steadier.
By location
- Peripapillary dominant: most lesions cluster around the optic disc and radiate outward.
- Mid-peripheral dominant: more lesions in the mid-periphery of the fundus.
- Posterior pole involvement: lesions nearer the macula; this matters because the macula controls sharp central vision.
By complications
- With cystoid macular edema (CME): swelling in the macula; often explains drop in central vision.
- With retinal vasculitis: leaking or inflamed blood vessels; can cause blurred vision and scotomas.
- With epiretinal membrane or atrophy: late structural changes that may reduce vision over time.
By functional loss on testing
- Cone-dominant dysfunction: worse light/contrast, color, and flicker problems.
- Rod-dominant dysfunction: worse night vision and dark adaptation.

These “types” overlap. The aim is to record what is active, where it is, and what problems it causes now.

Causes

Birdshot is not caused by germs. It is an autoimmune disease with a very strong genetic link. No single trigger explains every case. Below are 20 well-described or proposed contributors. Each is short and in plain words.

HLA-A29 genetic marker: Most patients carry HLA-A29. It does not “cause” the disease alone, but it makes the immune system more likely to react against the eye.
Specific HLA-A29 subtypes: Some A29 subtypes (like A*29:02) may carry higher risk. Subtypes change how immune cells present antigens.
Retinal/choroidal autoantigens: The immune system may learn to attack eye proteins. This “self-attack” produces deep choroidal spots.
T-cell–driven inflammation: Overactive T-cells (especially Th1/Th17) drive chronic, relapsing inflammation in the choroid and retina.
Antigen presentation in the choroid: Cells in the choroid present antigens in a way that sustains immune activation over time.
Molecular mimicry: A past exposure (for example, a microbe) may look like an eye protein, so the immune system crosses wires and attacks the eye.
Innate immune priming: The background “tone” of the immune system may be higher in some people, so inflammation starts more easily.
Breakdown of tolerance: The body normally prevents attack on self-tissues. In birdshot, that tolerance is weaker in the eye.
Choroidal vascular changes: Inflammation around choroidal vessels can reduce oxygen to the retina and promote more injury.
Cytokine imbalance: High levels of inflammatory messengers (like IL-6, IL-17, TNF-α) maintain a loop of ongoing inflammation.
Complement activation: Parts of the complement system may amplify local damage to the outer retina and choroid.
Microglial activation: The retina’s resident immune cells get “switched on,” adding to tissue stress and dysfunction.
Oxidative stress: Chronic inflammation increases oxidative injury, harming photoreceptors and retinal pigment epithelium (RPE).
Blood-retina barrier leak: Inflamed vessels leak fluid and cells into the retina, causing blur and macular edema.
Genetic background beyond HLA: Other immune genes may shape risk or severity, though not as strongly as HLA-A29.
Age-related immune changes: Birdshot usually starts in middle age; immune regulation shifts with age and may favor autoimmunity.
Hormonal factors: Subtle hormonal effects on immune balance may influence risk, though data are limited.
Environmental cofactors: Smoking, systemic inflammation, or other exposures may nudge a primed immune system toward disease.
Gut-eye axis (microbiome): Intestinal microbes can shape systemic immunity. Disturbance may tilt the immune system toward autoimmunity.
Persistent immune memory: Once primed, memory T-cells keep the response going, explaining chronic, bilateral disease.

Important note: These are mechanisms and risk influences. Birdshot is classically non-infectious and is not caused by a single pathogen.

Symptoms

Blurry vision: Vision may come and go, often worse during flares or when macular edema is present.
Floaters: Dark specks or cobwebs from inflammatory cells in the vitreous.
Poor night vision (nyctalopia): Trouble seeing in dim light due to rod dysfunction.
Photopsias: Flashes or shimmering lights from irritated retinal tissue.
Light sensitivity (photophobia): Bright light is uncomfortable because inflamed retina over-responds.
Color problems (dyschromatopsia): Colors look washed out or less rich, especially blues and greens.
Poor contrast: Gray-on-gray details are lost; text may look faded.
Wavy or distorted lines (metamorphopsia): A sign of macular swelling or retinal surface changes.
Dark or missing spots (scotomas): Patches in the visual field, often near the blind spot, that do not see well.
Difficulty reading: Letters fade, move, or blur with macular involvement.
Eye haze: Vision looks “milky” due to vitreous inflammation.
Headache or eye strain: From trying harder to focus and read in low contrast.
Reduced peripheral awareness: Bumping into objects due to subtle field loss.
Slow dark adaptation: Taking much longer to see after lights go off.
Stable vision between flares (then gradual decline): Some people feel “good days and bad days,” but notice slow change over years without treatment.

Diagnostic tests

(grouped into Physical Exam, Manual Tests, Lab/Pathology, Electrodiagnostic, and Imaging)

A. Physical exam

Best-corrected visual acuity (BCVA): Reading a letter chart with your best glasses. It measures central sharpness. In birdshot, acuity may be normal early, then drop with macular edema or atrophy. It does not show the whole story but is basic and important.
Slit-lamp exam with vitreous cell grading: The doctor looks for tiny white cells and haze in the jelly of the eye. The number and clarity measure inflammation. Birdshot often has mild-to-moderate vitreous cells even when the front of the eye is quiet.
Dilated fundus exam (indirect ophthalmoscopy): The doctor looks at the retina and choroid after dilation. The “cream birdshot spots” radiating from the disc are classic. The doctor also checks vessels for leak or inflammation and looks for macular swelling.

B. Manual tests

Amsler grid: A small grid held at reading distance. Wavy lines or missing boxes suggest macular involvement or scotomas. It is a simple way to monitor central changes at home.
Confrontation visual fields: The doctor checks side vision by finger counting or target movement. It can catch large blind areas but is less precise than automated testing.
Color vision plates (Ishihara): You name numbers within colored dots. Birdshot can lower color sensitivity, so errors may rise over time, especially with macular disease.

C. Laboratory and pathology

HLA-A29 typing: A blood test to see if the HLA-A29 marker is present. Most patients with birdshot are positive. A positive result supports the diagnosis in the right clinical picture but is not proof by itself.
Syphilis serology (e.g., RPR/VDRL and treponemal test): Used to exclude infectious uveitis that can mimic birdshot. A negative result helps rule out an important alternative.
Tuberculosis testing (IGRA or PPD) ± chest study: Birdshot is non-infectious, but TB uveitis can look similar. Negative TB tests support a non-TB cause.
Serum ACE and lysozyme: These help screen for sarcoidosis, another uveitis that can mimic birdshot. Normal results make sarcoid less likely.
ESR/CRP and basic autoimmune screen (e.g., ANA): General inflammation markers and broad autoimmunity screens. They are often normal in birdshot but help rule out other systemic causes.

D. Electrodiagnostic tests

Full-field electroretinogram (ffERG): Measures the retina’s global electrical response to flashes. Birdshot often reduces cone responses and 30-Hz flicker early and can also reduce rod signals. It is valuable to track function over time.
Multifocal ERG (mfERG): Maps function across many small retinal areas. It can detect regional dysfunction even before big changes are seen on imaging.
Visual evoked potentials (VEP): Measures electrical signals from the visual cortex after a checkerboard stimulus. It helps confirm signal delay or loss along the visual pathway when needed.

E. Imaging tests

Optical coherence tomography (OCT) of the macula: A “cross-section” scan of the retina that shows cystoid macular edema, epiretinal membrane, and atrophy. OCT explains many changes in acuity and distortion.
Enhanced-depth imaging OCT (EDI-OCT): Focuses deeper into the choroid. It can show choroidal thickening/thinning and structural changes where lesions lie.
Fluorescein angiography (FA): A dye test that shows leaky retinal vessels and macular leakage. It helps confirm vasculitis and guides treatment for edema.
Indocyanine green angiography (ICGA): Highlights the choroid. Birdshot lesions often appear as hypocyanescent (dark) spots on ICGA, sometimes more numerous than what is seen on color photos.
Fundus autofluorescence (FAF): Shows the health of the retinal pigment epithelium (RPE). Areas of stress may look bright; atrophy looks dark. It maps disease spread non-invasively.
Optical coherence tomography angiography (OCTA): A dye-free scan that shows the retinal and choroidal micro-vessels. It may show reduced flow or network changes in affected zones.

Non-pharmacological treatments (therapies & others)

Low-vision rehabilitation and training
A low-vision specialist teaches practical ways to use remaining sight—high-contrast reading materials, large-print devices, magnifiers, task lighting, and orientation techniques. The purpose is to keep daily life safe and productive while medical therapy controls inflammation. The mechanism is not biological; it is functional—optimizing contrast, magnification, and lighting reduces the strain created by reduced sensitivity and night-vision problems common in birdshot. Early referral helps people stay independent during disease flares or while waiting for treatments to work. Programs also introduce phone apps and electronic readers that enlarge text and boost contrast. Family training improves home lighting, label readability, and step safety. This non-drug approach does not treat inflammation, but it protects quality of life while you and your doctor build a long-term plan. AAO
Blue-blocking and glare-reducing filters
Special lenses and clip-on filters cut glare and improve contrast. The purpose is to reduce photophobia and washed-out vision that come from retinal inflammation. Mechanistically, filtering short-wavelength light decreases scatter within inflamed ocular media and enhances signal-to-noise reaching photoreceptors, which can help activities under bright indoor lighting or sun. Lenses with side shields and wraparound frames further reduce stray light and wind. While filters do not alter disease activity, many patients report better comfort and safer mobility outdoors, which matters when dark adaptation is slow. An optometrist familiar with uveitis can trial different tints (amber, brown, gray) under real-world conditions to find the best compromise between brightness and color accuracy for driving, reading street signs, and computer work. AAO
Task-specific lighting and contrast optimization
Directed lamps, under-cabinet lighting, and matte surfaces cut shadows and reflections that make print hard to read. The purpose is to make near tasks (reading, cooking, medication labeling) more reliable despite decreased retinal sensitivity. Mechanism: boosting luminance at the target and reducing background glare raises effective contrast so letters “stand out,” letting you use lower magnification and reduce eye fatigue. Occupational therapists can audit your home and work to recommend lamp placement, bulb types, and high-contrast labels. This is a fast, safe win while medical therapy unfolds. AAO
Smoking cessation
Stopping smoking protects retinal and choroidal circulation and reduces oxidative and inflammatory stress. The purpose is to lower background inflammation and vascular risk that can worsen any posterior uveitis. Mechanism: tobacco smoke promotes systemic cytokine release, endothelial dysfunction, and oxidative injury; quitting lessens these drivers and may improve steroid response and wound healing if surgery or implants are needed. Clinicians typically combine counseling, nicotine replacement, or prescription aids. AAO
Cardiometabolic health (blood pressure, lipids, exercise)
Maintaining healthy blood pressure, glucose, and lipids protects retinal microvasculature and the optic nerve. The purpose is to keep the eye resilient and reduce risks from corticosteroids (like elevated blood sugar or blood pressure). Mechanism: aerobic activity and weight control improve endothelial function and systemic inflammatory tone, complementing medical therapy. Even brisk walking most days helps. Your eye team may coordinate with a primary-care clinician to align goals. Cleveland Clinic
Sleep optimization
Consistent, quality sleep supports immune balance and daytime visual function. The purpose is less fatigue and better symptom tolerance. Mechanism: regular sleep helps regulate immune signaling and cortisol rhythms, which may indirectly influence flare patterns and the experience of glare and contrast loss. Simple steps—fixed bedtimes, dark rooms, reduced evening screens—are first-line. Cleveland Clinic
Stress-reduction practices (mindfulness, CBT, relaxation)
Chronic disease raises stress, which can worsen symptom perception and adherence. The purpose is to improve coping, medication consistency, and pain or glare tolerance. Mechanism: relaxation techniques lower sympathetic arousal and systemic cytokines modestly, supporting overall well-being alongside drug therapy. Short daily breathing sessions or guided apps are practical. Cleveland Clinic
Safe-driving strategies
Night blindness and glare can make driving hard. The purpose is safety—plan routes with better lighting, avoid night or storm driving early in treatment, keep windshields clean, use anti-glare night settings, and sit closer to the wheel within safety limits for dashboard visibility. Mechanism: reducing glare input and cognitive load helps compensate for delayed dark adaptation and reduced contrast sensitivity. Discuss driving fitness with your eye doctor. AAO
Amsler grid and symptom journaling
Simple at-home checks can catch new scotomas, metamorphopsia, or blur sooner. The purpose is early detection of flares or macular edema changes. Mechanism: regular self-testing increases the chance of timely evaluation and treatment adjustments. Record floaters, flashes, and glare levels; bring the log to visits. AAO
Vaccination planning (non-live vaccines as appropriate)
Because many patients require immunosuppressants, up-to-date vaccines (like influenza and pneumococcal per local guidance) lower infection risks. Purpose: prevent infections that can interrupt or complicate uveitis therapy. Mechanism: reducing infectious triggers and systemic illness helps keep inflammation stable and minimizes treatment gaps. Always coordinate timing with your prescribing specialist. NCBI
UV and wind protection outdoors
Wraparound sunglasses and hats shield ocular surfaces from UV and airborne irritants that amplify photophobia. Purpose: comfort and prevention of surface inflammation that can worsen visual quality. Mechanism: reducing light scatter and surface dryness improves day comfort. AAO
Workplace/ergonomic adjustments
Larger monitors, high-contrast themes, screen magnifiers, and frequent “eye breaks” reduce fatigue. Purpose: maintain productivity while managing chronic disease. Mechanism: simple ergonomic changes offset contrast and photophobia limitations. AAO
Fall-prevention at home
Night-lights, stair rails, and non-slip mats lower injury risk during low-light navigation when night vision is poor. Purpose: safety. Mechanism: environmental control compensates for nyctalopia common in birdshot. AAO
Peer support and education
Understanding the disease improves confidence and adherence. Purpose: better long-term outcomes through informed choices and timely reporting of side effects (e.g., steroid-related eye pressure). Mechanism: education turns vague symptoms into actionable observations for clinicians. AAO
Eye-strain hygiene for screens
20-20-20 rule (breaks), proper font sizes, and night modes ease symptoms. Purpose: comfort during computer work. Mechanism: reduces accommodative strain and glare sensitivity. AAO
Nutrition pattern for eye and vascular health
While no diet cures birdshot, a Mediterranean-style pattern (leafy greens, fish, nuts) supports vascular health and complements therapy. Purpose: systemic support. Mechanism: anti-inflammatory and antioxidant nutrient mix may help retinal resilience. Diet is adjunctive, not a treatment. Cleveland Clinic
Medication adherence tools
Pill boxes, reminders, and caregiver help prevent missed doses that trigger flares. Purpose: consistent control. Mechanism: sustained therapeutic levels reduce relapse. AAO
Regular comprehensive follow-up
Scheduled exams with OCT, fields, and ERG tracking catch changes early. Purpose: data-driven adjustments. Mechanism: objective metrics of retina function and edema guide therapy before vision drops. AAO
Sunset and low-light planning
Plan errands in brighter hours while night sensitivity is being managed. Purpose: safety and reduced stress. Mechanism: aligns activities with visual strengths. AAO
Co-management with systemic specialists
Because birdshot is autoimmune, coordination with rheumatology or immunology ensures safe use of biologics and immunosuppressants. Purpose: minimize systemic risks while achieving ocular control. Mechanism: shared monitoring (labs, infection screening) supports continuity. NCBI

Drug treatments

Adalimumab (Humira® and biosimilars: Amjevita®, Hyrimoz®, Hulio®) — TNF-α inhibitor
Purpose: control noninfectious intermediate/posterior/panuveitis to preserve vision. Mechanism: neutralizes TNF-α, a central inflammatory cytokine in uveitis. Dosing (adults, label): initial 80 mg, then 40 mg every other week starting 1 week later (product-specific). Timing: weeks to onset; sustained dosing for maintenance. Side effects: injection site reactions, increased infection risk (screen for TB/hepatitis), rare demyelination/malignancy per label. Notes: FDA-approved for noninfectious uveitis; widely used as a steroid-sparing agent in birdshot. Biosimilars share the reference indication and dosing. NCBI+4FDA Access Data+4FDA Access Data+4
Dexamethasone intravitreal implant (Ozurdex®) — corticosteroid
Purpose: treat noninfectious posterior-segment uveitis and uveitic macular edema. Mechanism: local steroid dampens ocular cytokines, stabilizes the blood-retina barrier, and reduces edema. Dosing (label): 0.7 mg intravitreal implant, repeated per clinician judgment. Timing: onset within weeks; effect lasts ~3–4 months. Side effects: elevated intraocular pressure (IOP), cataract, infection risk; label lists contraindications such as active ocular infection or advanced glaucoma. Notes: FDA-approved for noninfectious posterior uveitis. Often used for focal edema or when systemic therapy is not tolerated. FDA Access Data+1
Fluocinolone acetonide intravitreal implant 0.18 mg (Yutiq®) — corticosteroid
Purpose: long-term control of chronic noninfectious uveitis affecting the posterior segment. Mechanism: sustained micro-dose steroid release reduces recurrent inflammation and macular edema for years. Dosing (label): single 0.18 mg implant per affected eye. Timing: designed for multi-year drug delivery; trials show lower relapse vs. sham but higher cataract and IOP events. Side effects: cataract, IOP elevation needing drops or surgery, endophthalmitis risk. Notes: FDA-approved for NIU-posterior; a durable local option when frequent injections or systemic drugs are not ideal. FDA Access Data+1
Fluocinolone acetonide intravitreal implant 0.59 mg (Retisert®) — corticosteroid
Purpose: long-term suppression of chronic noninfectious posterior uveitis. Mechanism: surgically placed implant releases steroid for ~30 months, lowering relapse. Dosing (label): one implant surgically sutured in the posterior segment. Timing: sustained effect over years; often reserved for severe, recurrent disease. Side effects: high rates of cataract and IOP rise (many need glaucoma surgery), infection/surgical risks. Notes: FDA-approved for NIU-posterior; evidence shows reduced relapse with significant IOP and cataract burden. FDA Access Data+2FDA Access Data+2
Triamcinolone acetonide, suprachoroidal (Xipere®) — corticosteroid for uveitic macular edema
Purpose: reduce macular edema associated with uveitis and improve vision. Mechanism: delivers steroid via the suprachoroidal space to the posterior segment while limiting anterior exposure. Dosing (label): 4 mg (0.1 mL of 40 mg/mL) via suprachoroidal injection using the SCS Microinjector; repeat per clinician. Timing: improvements in retinal thickness and vision over weeks. Side effects: IOP rise, cataract, injection-related events; follow label technique to reduce complications. Notes: FDA-approved for uveitic macular edema; useful adjunct when edema dominates symptoms. FDA Access Data+2FDA Access Data+2
Systemic corticosteroids (e.g., prednisone) — corticosteroid
Purpose: rapid control of active inflammation at diagnosis or flares. Mechanism: broad cytokine suppression; stabilizes blood-retina barrier and quiets vitreous cells/vasculitis. Dosing: individualized; often a short high-dose course then taper while steroid-sparing agents begin working. Timing: days to weeks for improvement. Side effects: weight gain, hyperglycemia, hypertension, mood changes, bone loss; use gastric and bone protection and monitor IOP. Notes: cornerstone of induction but long-term monotherapy is avoided due to toxicity; commonly transitioned to immunomodulators/biologics. (General clinical practice summaries.) NCBI+1
Mycophenolate mofetil — antimetabolite (off-label in birdshot)
Purpose: steroid-sparing maintenance of quiescence. Mechanism: inhibits inosine monophosphate dehydrogenase to limit lymphocyte proliferation, reducing autoimmune attack in the choroid/retina. Dosing: commonly 1–1.5 g twice daily (clinician-directed). Timing: several weeks to effect; monitor CBC and liver function. Side effects: GI upset, cytopenias, infection risk, teratogenicity. Notes: widely used in noninfectious uveitis cohorts including birdshot, often combined with low-dose steroids or biologics. NCBI+1
Azathioprine — antimetabolite (off-label)
Purpose: steroid-sparing control of chronic inflammation. Mechanism: purine analog; decreases proliferating T and B cells. Dosing: typically 1–2 mg/kg/day after TPMT/NUDT15 metabolism screening. Timing: 6–12 weeks to effect; monitor CBC/LFTs. Side effects: cytopenias, hepatotoxicity, infection risk. Notes: long history in uveitis maintenance when biologics are unavailable or contraindicated. NCBI
Methotrexate — antimetabolite (off-label)
Purpose: maintenance control, often weekly dosing with folic acid. Mechanism: inhibits dihydrofolate reductase and AICAR transformylase, reducing inflammatory cell proliferation and cytokines. Dosing: weekly (oral or subcutaneous) per clinician; folic acid co-prescribed. Timing: 6–12 weeks; labs for liver, blood counts. Side effects: mouth sores, liver enzyme rise, cytopenias, teratogenicity. Notes: common, cost-effective option across noninfectious uveitis types. NCBI
Cyclosporine — calcineurin inhibitor (off-label)
Purpose: steroid-sparing agent especially when T-cell–mediated inflammation is suspected. Mechanism: blocks calcineurin to reduce IL-2–driven T-cell activation. Dosing: individualized to trough levels and side-effects. Timing: weeks; monitor kidney function and blood pressure. Side effects: nephrotoxicity, hypertension, tremor, gingival hyperplasia. Notes: part of classic birdshot regimens before biologics became common. PMC
Tacrolimus — calcineurin inhibitor (off-label)
Purpose: alternative to cyclosporine for T-cell modulation with a different side-effect profile. Mechanism: FKBP-12 binding to inhibit calcineurin; reduces T-cell activation. Dosing: clinician-directed with trough monitoring. Side effects: nephrotoxicity, hypertension, neurotoxicity; monitor labs. Notes: used in refractory cases or intolerance to other antimetabolites. PMC
Infliximab (Remicade®; infliximab-dyyb biosimilar Inflectra®) — TNF-α inhibitor (off-label for uveitis subtypes including birdshot)
Purpose: systemic control in refractory disease when adalimumab is insufficient or not tolerated. Mechanism: chimeric monoclonal antibody neutralizing TNF-α. Dosing: IV infusions with induction then maintenance (e.g., 5 mg/kg at weeks 0, 2, 6 then every 4–8 weeks; clinician-directed). Side effects: infusion reactions, infection risk, TB reactivation; boxed warnings on serious infections and malignancy in label. Notes: not specifically FDA-approved for uveitis, but supported by uveitis case series; use per specialist judgment. FDA Access Data+1
Interferon-α (off-label)
Purpose: steroid-sparing control in selected refractory cases. Mechanism: immunomodulation that shifts T-cell activity and down-regulates pro-inflammatory cytokines. Dosing/Timing: specialist-directed; monitor mood, thyroid, and blood counts. Side effects: flu-like symptoms, depression, cytopenias. Notes: used in Europe for certain posterior uveitis, including birdshot, in experienced centers. PMC
Tocilizumab — IL-6 receptor inhibitor (off-label)
Purpose: rescue therapy for refractory uveitic macular edema or persistent inflammation after TNF-α blockade. Mechanism: blocks IL-6 signaling. Dosing: IV or SC per rheumatology protocols. Side effects: infection risk, elevated lipids, liver enzymes. Notes: evidence from refractory NIU cohorts; coordinate with rheumatology. PMC
Rituximab — anti-CD20 B-cell depleter (off-label)
Purpose: rare, refractory birdshot cases when other systemic agents fail. Mechanism: B-cell depletion reduces antigen presentation and cytokines that fuel ocular inflammation. Dosing: oncology or rheumatology schedules; monitor for infusion reactions and infections. Side effects: infusion reactions, hypogammaglobulinemia, reactivation risks. Notes: limited-case reports in NIU. PMC
Acthar® Gel (repository corticotropin) — ACTH analog
Purpose: adjunct for inflammatory eye diseases when other steroids are not suitable. Mechanism: stimulates endogenous corticosteroid production and may have melanocortin receptor anti-inflammatory actions. Dosing: varied; clinician-directed courses. Side effects: steroid-like effects (hypertension, hyperglycemia), edema; product labeling lists extensive precautions. Notes: label and HCP resources include posterior uveitis among listed ophthalmic inflammatory conditions; use is individualized. FDA Access Data+2actharhcp.com+2
Topical corticosteroids (as adjuncts)
Purpose: reduce anterior segment spillover inflammation even when the main disease is posterior. Mechanism: local steroid reduces cells and flare in the anterior chamber and photophobia. Dosing: per ophthalmologist; taper to avoid rebound. Side effects: IOP rise, cataract with chronic use. Notes: adjunct, not primary control for birdshot’s posterior disease. AAO
Periocular triamcinolone (sub-Tenon’s) — corticosteroid injection
Purpose: focal control of posterior segment inflammation or macular edema when systemic therapy is not desired. Mechanism: depot steroid diffuses to macula/choroid. Side effects: IOP rise, ptosis, globe perforation risk (rare). Notes: used selectively; increasingly supplanted by implants with known release profiles. PMC
Combination therapy (biologic + antimetabolite)
Purpose: improve durability and allow lower steroid exposure. Mechanism: complementary cytokine and proliferation blockade. Side effects: cumulative infection risks; careful lab and symptom monitoring required. Notes: common in refractory birdshot cohorts to keep eyes quiet long term. PMC
Rescue corticosteroid pulses (IV methylprednisolone)
Purpose: rapidly quiet severe flares threatening central vision. Mechanism: high-dose steroid quickly reduces cytokines and vascular leakage; typically followed by taper and maintenance immunomodulation. Side effects: transient mood changes, hyperglycemia, sleep disruption; monitored setting. Notes: used for vision-threatening relapses. NCBI

Dietary molecular supplements

Lutein + Zeaxanthin
These carotenoids concentrate in the macula and filter blue light, potentially improving contrast and glare tolerance. Typical eye-health doses are lutein 10 mg + zeaxanthin 2 mg daily (as used in AREDS2-style formulations). Purpose: support macular pigment and antioxidant defenses; mechanism: quenching reactive oxygen species and filtering short-wavelength light to reduce phototoxic stress during chronic inflammation. Not a treatment for birdshot itself, but may help comfort with light and contrast while medical therapy controls inflammation. Cleveland Clinic
Omega-3 fatty acids (EPA/DHA)
Common dosing is 1–2 g/day combined EPA+DHA from fish oil. Purpose: systemic anti-inflammatory support and potential tear-film comfort. Mechanism: omega-3s shift eicosanoid balance toward less-inflammatory mediators and generate resolvins; this may slightly lower inflammatory tone that contributes to macular edema risk. Evidence is mixed for ocular diseases and does not replace immunosuppression, but omega-3s can fit a heart-healthy plan. Cleveland Clinic
Vitamin D (repletion if low)
If blood levels are low, clinicians may replete with 800–2000 IU/day (or as prescribed). Purpose: correct deficiency that may worsen immune dysregulation and bone risks from steroids. Mechanism: vitamin D modulates innate and adaptive immunity and supports bone mineralization during steroid therapy. Over-supplementation is unsafe; follow labs. Cleveland Clinic
N-Acetylcysteine (NAC)
Typical general doses 600–1200 mg/day. Purpose: antioxidant support. Mechanism: replenishes intracellular glutathione and may counter oxidative stress in chronically inflamed tissues. It is adjunctive only; discuss drug interactions. Cleveland Clinic
Alpha-lipoic acid
Often 300–600 mg/day. Purpose: antioxidant and mitochondrial cofactor that may protect neural tissues under oxidative stress. Mechanism: scavenges reactive species and recycles other antioxidants. Evidence specific to birdshot is lacking; treat as supportive wellness under clinician guidance. Cleveland Clinic
Zinc (with copper balance)
Common multinutrient amounts are 8–15 mg/day zinc with 1–2 mg copper if high-dose zinc is used. Purpose: immune function and ocular antioxidant enzymes (e.g., superoxide dismutase cofactor). Mechanism: supports normal immune signaling; excessive zinc can cause copper deficiency—avoid high doses unless prescribed. Cleveland Clinic
Curcumin (turmeric extract with piperine for absorption)
Doses vary widely (e.g., 500–1000 mg/day standardized curcuminoids). Purpose: gentle systemic anti-inflammatory support. Mechanism: down-regulates NF-κB and related cytokines; bioavailability is a challenge, so formulated products are used. This is supportive, not disease-modifying in birdshot. Cleveland Clinic
Coenzyme Q10
Typical 100–200 mg/day. Purpose: mitochondrial antioxidant that may help general retinal metabolic health. Mechanism: electron transport support and free-radical scavenging. Consider if on statins (which can lower CoQ10), but coordinate with your physician. Cleveland Clinic
Resveratrol
Common 100–250 mg/day in supplements. Purpose: antioxidant/anti-inflammatory polyphenol. Mechanism: influences NF-κB and sirtuin pathways; human ocular data are limited, so treat as optional adjunct. Cleveland Clinic
Quercetin
Often 250–500 mg/day. Purpose: plant flavonoid with antioxidant actions. Mechanism: can modulate mast-cell activation and oxidative pathways; solid birdshot-specific evidence is lacking. Discuss with your doctor regarding interactions (e.g., with antibiotics). Cleveland Clinic

Immunity-booster / regenerative / stem-cell” drugs

There are no approved “stem-cell drugs” or regenerative medicines for birdshot uveitis. Transplant-style cellular therapies remain experimental and are not recommended outside trials due to safety and uncertain benefit. If you read about such products online, be careful; many are unregulated. What is evidence-based in birdshot are immunosuppressants and targeted biologics listed above, plus approved steroid implants/injections for NIU or uveitic macular edema. For patients needing a different kind of systemic steroid modulation, Acthar Gel is an FDA-labeled option for ophthalmic inflammatory conditions, but its use is individualized and not a cure. Always prioritize therapies with strong safety oversight and published evidence. PMC+1

(If your aim is “immune support,” clinicians typically focus on vaccine planning, infection screening, bone/pressure protection, and nutrition/sleep—rather than unproven “immune boosters.”) NCBI

Surgeries (procedures and why they’re done)

Surgical placement of Retisert® implant
Procedure: an ophthalmic surgeon implants the 0.59 mg fluocinolone device into the posterior segment under sterile conditions. Why: to deliver long-term steroid locally when chronic, recurrent inflammation threatens vision or when other options fail. It lowers relapse risk but frequently causes cataract and IOP rise, so patients often need cataract and/or glaucoma surgery later. FDA Access Data+1
Cataract extraction (phacoemulsification with intraocular lens)
Procedure: remove a cloudy lens and insert a clear implant. Why: chronic steroids and inflammation accelerate cataract; clearing the lens improves acuity and glare, enabling better monitoring and function. Timing is coordinated with uveitis control to reduce postoperative flares. AAO
Glaucoma surgery (trabeculectomy or tube shunt)
Procedure: create new outflow pathways to reduce eye pressure. Why: steroid implants/injections and chronic inflammation can raise IOP; medications sometimes fail, and surgery is required to protect the optic nerve. FDA Access Data
Pars plana vitrectomy
Procedure: remove the vitreous gel to clear dense floaters, retrieve samples (if needed), relieve traction, or assist with membrane peeling. Why: vision-degrading floaters or epiretinal membranes can persist even when inflammation is controlled. Vitrectomy can improve clarity and facilitate drug delivery. PMC
Periocular/intravitreal injection procedures (Ozurdex®, Yutiq®, Xipere®)
Procedure: office-based injections or microinjection (for suprachoroidal) under sterile technique. Why: targeted steroid delivery to calm intraocular inflammation or macular edema without full-body exposure. These are procedural rather than “surgeries,” but they follow operating-room-like sterility to prevent infection. FDA Access Data+2FDA Access Data+2

Preventions

Keep scheduled eye visits for OCT/ERG/angiography so relapses are caught early. AAO
Take medicines exactly as prescribed; use reminders to prevent gaps. PMC
Report new floaters, flashes, dark spots, or sudden blur immediately—do not wait. AAO
Discuss vaccines and infection screening before starting immunosuppressants/biologics. NCBI
Protect from glare and UV with wraparound eyewear and hats. AAO
Avoid smoking; it worsens vascular and inflammatory risk. Cleveland Clinic
Control blood pressure, glucose, and lipids to support retinal health. Cleveland Clinic
Plan driving and night activities conservatively while symptoms are active. AAO
Maintain nutrition and sleep to support overall health during treatment. Cleveland Clinic
Coordinate with rheumatology/immunology to monitor labs and safety. NCBI

When to see a doctor urgently

Call or visit promptly if you notice sudden vision loss, a new dark curtain or scotoma, a burst of floaters or flashes, pain/redness with light sensitivity, distorted lines, or headache with halos (possible high eye pressure). Also seek help if you develop fever, cough, weight loss, or unusual infections while on immunosuppressants or biologics, or before eye procedures if you may have an infection. Timely care protects sight and guides safe medication use. AAO+1

Foods to prefer and to limit/avoid

What to eat (examples):
Choose a Mediterranean-style pattern: leafy greens (spinach, kale), colorful vegetables, legumes, whole grains, fish (salmon, sardines for omega-3s), nuts (walnuts, almonds), olive oil, berries, citrus, and adequate hydration. Purpose: support vascular and retinal health during long-term therapy; mechanism: antioxidants and healthy fats may reduce systemic inflammatory tone. This is supportive—not a treatment for inflammation—so keep all prescribed medicines and visits. Cleveland Clinic

What to limit/avoid (examples):
Ultra-processed foods high in added sugar, trans fats, and excess salt; heavy alcohol; tobacco; and energy drinks that worsen sleep or blood pressure. Purpose: avoid spikes that strain vessels and metabolism, which matter if you use steroids or immunosuppressants. Mechanism: minimizing pro-inflammatory and hypertensive triggers supports eye and whole-body health. Cleveland Clinic

Frequently asked questions

Is birdshot choroiditis an infection?
No. It is an autoimmune posterior uveitis, strongly associated with HLA-A29, not caused by a germ. NCBI+1
What exactly are “birdshot” lesions?
Cream-colored, oval spots in the choroid around the optic nerve, arranged radially—classic for this disease. BioMed Central
Who gets it?
Usually adults, often of European ancestry, with a striking link to HLA-A29. PMC+1
How is it diagnosed?
By clinical appearance plus imaging (OCT, fluorescein and indocyanine green angiography) and supportive HLA-A29 testing; ERG often shows retinal dysfunction. AAO
Is it curable?
There is no “once-and-done” cure, but long-term control is common using immunosuppression and/or approved ocular steroid implants/injections. FDA Access Data+1
Will I go blind?
With modern therapy and close follow-up, many patients maintain functional vision, especially if macular edema and inflammation are controlled early. AAO
What treatments are FDA-approved for eye inflammation in this condition?
Adalimumab (and its biosimilars) for noninfectious uveitis; Ozurdex for NIU-posterior; Yutiq and Retisert for chronic NIU-posterior; Xipere for uveitic macular edema. Systemic steroids and other immunosuppressants are used per specialist judgment. FDA Access Data+4FDA Access Data+4FDA Access Data+4
Why do many patients still need cataract or glaucoma care?
Steroids—especially implants—raise IOP and hasten cataracts; surgery may be needed to protect sight. FDA Access Data
How long will I be on treatment?
Often years. The aim is quiet eyes on the lowest effective therapy with regular monitoring. AAO
Can I drive?
Yes if vision meets legal standards, but night driving may be difficult; plan conservatively and reassess as treatment works. AAO
Is HLA-A29 testing required?
It strongly supports the diagnosis but is not the only criterion; doctors use the whole clinical picture. BioMed Central
What tests follow me over time?
OCT for macular edema, visual fields, ERG for retinal function, angiography for leakage/lesions—scheduled at intervals. AAO
Are biologics safe?
They can be very effective; labels warn about infections and other risks—hence TB/hepatitis screening and ongoing lab checks. FDA Access Data
Do diet and supplements replace medicine?
No. They are supportive only. Always continue prescribed therapy and coordinate supplements with your clinicians. Cleveland Clinic
What happens if I miss doses?
Flares may recur and vision can worsen; use reminders and call your clinic if a gap occurs. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.